Oculis Holding AG
NASDAQ:OCS
Oculis Holding AG
Other Items
Oculis Holding AG
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Oculis Holding AG
NASDAQ:OCS
|
Other Items
-CHf59.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Other Items
-$977m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
38%
|
CAGR 10-Years
18%
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Other Items
-CHf597m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
24%
|
CAGR 10-Years
-14%
|
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Other Items
-$196m
|
CAGR 3-Years
-303%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Oculis Holding AG
Glance View
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The company is headquartered in Zug, Zug and currently employs 28 full-time employees. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
See Also
What is Oculis Holding AG's Other Items?
Other Items
-59.5m
CHF
Based on the financial report for Dec 31, 2025, Oculis Holding AG's Other Items amounts to -59.5m CHF.
What is Oculis Holding AG's Other Items growth rate?
Other Items CAGR 1Y
-276%
Over the last year, the Other Items growth was -276%.
